ANZCTR search results

This co-designed single-arm feasibility study explored whether or not a tailored exercise program was feasible, safe and acceptable to implement, in people living with a stoma and without a parastomal hernia, It was delivered by skilled physiotherapists, with individual personally tailored sessions, face to face over a 3-month period, with 12 people completing the program. It had no major adverse events and those living with a stoma, without a parastomal hernia, reported positive experiences.

The purpose of this study is to find out whether the number of heart operations performed on people aged 90 years and older in Australia and New Zealand has changed over the past 15 years, and whether patients treated in public hospitals have different outcomes from those treated in private hospitals. To do this, we will look back at existing de-identified records held in a national intensive care registry for every patient aged 90 or older who was admitted to intensive care after open heart surgery, a heart valve operation, a coronary artery bypass, or both together, between 1 January 2010 and 31 December 2024. This is an observational study: we will only study information that has already been collected as part of routine care, so there is no new treatment, no randomisation into groups, and no contact with patients; the two groups being compared are simply patients treated in public hospitals and patients treated in private hospitals. We expect to find that the share of these operations taking place in public hospitals has fallen over time, and this is our main hypothesis; we also want to learn whether the sector of the hospital is linked to a patient's chance of going straight home after surgery, being transferred to another hospital, dying in intensive care or in hospital, or surviving over the following years. Because the two groups of patients may differ from the outset, we will take account of measured differences such as age, sex, type of operation, whether the surgery was planned or urgent, the year of surgery, and the level of social advantage in the area where the patient lives. Finally, we will check how well an existing risk score used in Australian and New Zealand intensive care units predicts death in hospital for patients of this age, so that in future patients and their families can be given more accurate information when deciding whether to proceed with surgery.

This study is aiming to evaluate the feasibility of a novel shared care model involving general practitioners (GPs) and genetic counsellors (GCs) who will deliver multifactorial breast and ovarian cancer risk assessment to people aged 20-39 years-old Who is it for? You may be eligible to join this study if you are aged between 20 to 39 years old, recorded female at birth and registered as a patient at one of the ten general practices involved in the trial, in metropolitan or regional areas of Victoria. Participating clinics will advertise directly to their eligible clients. Note: this is a trial for people without a diagnosed cancer. Study details This is a 2x2 factorial cluster allocation and randomised feasibility study. All eligible participants will be contacted, informed of the trial and provided with access to a breast and ovarian cancer risk assessment. The mode of the access to the cancer risk assessment will be determined by the how the GP clinic is allocated: either through a GP (GP-facilitated access) or through participant self-access (consumer led-access). After accessing the risk assessment, participants will be asked to provide DNA for testing (saliva test kit) and enter data about their health history and family cancer history into a secure online portal. Study genetic counsellors will then collate the genetic and health history data to generate a breast and ovarian cancer risk assessment result. Consumer participants will then be randomised to receive these results through their GP or by a genetic counsellor. Participants will complete surveys at 2 weeks and 3 months post-results delivery to assess whether they thought the intervention was acceptable and determine effect on psychosocial outcomes such as cancer worry. This feasibility trial will provide important information on how to improve access to multifactorial breast and ovarian cancer risk assessments to the general population. It is hoped that this research will define appropriate access and results-delivery pathways for young people seeking breast and ovarian cancer risk assessments via primary care. By providing access to these breast and ovarian cancer risk assessments at a younger age, it is hoped that young people identified at higher risk of developing cancer will have access to earlier screening and better treatment options.

This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular hypertension. The study aims to determine whether TB0001 lowers eye pressure as effectively as timolol, a commonly used glaucoma eye drop, while remaining safe and well tolerated. Participants will be randomly assigned to receive one of three strengths of TB0001 or timolol for 28 days. Eye pressure, eye health, side effects and tolerability will be assessed throughout the study. The results will help identify the most appropriate dose of TB0001 for future clinical studies.

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality among women. The postpartum period, marked by physiological changes of pregnancy, can exacerbate existing CVD risk factors and presents an ideal opportunity for prevention. Postpartum women at high risk for CVD often receive insufficient targeted care, leading to missed opportunities for early intervention and prevention. This pilot research study aims to investigate the impact of a novel Telehealth Clinical Pilates program specifically designed for postpartum women at high risk of CVD. Addressing this gap is crucial for improving maternal health outcomes and reducing long-term chronic disease and associated healthcare costs. The insights gained from this pilot study could inform larger, more comprehensive studies and ultimately lead to significant changes in postpartum care practices.

The ACE Your Hearing study aims to improve the lives of adults over 50 with hearing loss and their families by providing a redesigned communication and wellbeing program. The primary purpose is to test if this modular, psychosocially-focussed program is more effective than standard care in reducing loneliness and improving emotional wellbeing. We hypothesise that participants who complete the program will report significantly better social participation and communication success compared to those receiving treatment-as-usual. To ensure these benefits reach the community, the study is being conducted within real-world hearing clinics to evaluate how easily the program can be integrated into everyday business operations. Ultimately, this research seeks to transform hearing care from a focus on devices alone to a holistic approach that supports the overall quality of life for Australians with hearing loss.

This study aims to find out whether a structured decision-making pathway can help adults make better-informed choices when considering treatment for benign skin lumps. Patients are supported by clinic staff and nurses to identify what matters most to them, and then discuss with their doctor the benefits and disadvantages of options such as surgery, less invasive treatment, or having no procedure. We expect that this approach will help patients choose treatment that better matches their personal priorities and expectations and will reduce regret about their decision afterwards. The outcomes of patients receiving this pathway will also be considered in comparison with information from patients who received usual care before the pathway was introduced.

Brief description of the study purpose: This project aims to co-design a practical set of tools and resources called the Nursing Compendium for Genomic-Informed Care (NGenCare) to help nurses and other health professionals integrate genomics into their routine cancer care. This project will co-design and develop the compendium, based on understanding the experiences and needs of both healthcare professionals and consumers. Who is it for? You may be eligible for this study if you are male or female, aged 18 or over, and within any of the cancer care networks below: • Consumers and their families or carers who are waiting in the Cancer Care Services Outpatient Clinics. • key stakeholders including consumers representatives, geneticists, genetic counsellors, nursing staff, medical staff and administration officers as identified by project Investigators within the Cancer Care network. Study details Interviews / Focus groups (clinician or health service staff member) - assist in mapping existing genomic service pathways to inform resources. Demographic data will be collected. Workshops (health services, clinicians and consumers) - develop, refine and discuss the delivery of these resources. Demographic data will be collected. This research is intended to be used to improve health outcomes and it is hoped that the results from this study will help develop the compendium and support nurses to confidently use genomics, improve access to more personalised and effective care for people with cancer.

Brief description of the study purpose The PRELuDE study aims to test whether personalised radionuclide treatment planning using a low dose tracer scan can accurately predict tumour radiation dose and improve how ¹77Lu PSMA radioligand therapy is prescribed for people with metastatic castration resistant prostate cancer. Who is it for? You may be eligible for this study if you are aged 18 years or older with metastatic castration resistant prostate cancer who have progressive disease despite standard treatments, have PSMA positive metastatic disease on imaging, adequate organ function, and are eligible to receive 177Lu PSMA therapy. Study details All participants will receive standard 177Lu PSMA therapy at a dose of 7400–8500 MBq for two treatment cycles. Participants will receive a tracer dose of 1000 MBq 177Lu PSMA before treatment. They will then undergo serial whole body planar imaging and SPECT CT scans at approximately 4 hours, 1 day, and 3–5 days after tracer injection to measure how much radiation is delivered to tumours and normal organs. These measurements will be used to calculate the predicted biologically effective dose (BED). The BED predicted from the tracer study will be compared with the BED measured after therapeutic administration using repeat imaging at the same time points. It is hoped that this research will validate a method for prospectively predicting tumour radiation dose, enabling more precise, efficient, and personalised radioligand therapy and improving treatment outcomes for people with advanced prostate cancer.

To examine the effect of a dedicated proactive multidisciplinary team review on blood glucose control and associated complications from compared with usual care. It is hypothesised that this intervention will result in reduced incidence of hospital acquired infection and improved blood sugar control.